Compass Therapeutics, Inc. (CMPX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Thomas J. Schuetz M.D., Ph.D.
|
CEO & Vice Chairman | 1.03M | -- | 1961 |
|
Mr. Barry Shin J.D., M.B.A.
|
Chief Financial Officer | 717k | -- | 1972 |
|
Mr. Jonathan E. Anderman J.D.
|
Senior VP, General Counsel & Corporate Secretary | 648k | -- | 1983 |
|
Mr. Neil L. Lerner CPA
|
Senior VP & Chief Accounting Officer | -- | -- | 1967 |
|
Mr. Bing Gong Ph.D.
|
Chief Scientific Officer | -- | -- | 1976 |
|
Anna Gifford
|
Senior Manager of Communications & Chief of Staff | -- | -- | -- |
|
Ms. Karin Herrera B.A.
|
Senior VP & Head of Clinical Operations | -- | -- | -- |
|
Dr. James Kranz Ph.D.
|
VP and Head of Chemistry Manufacturing & Controls | -- | -- | -- |
|
Dr. Cynthia A. Sirard M.D., Ph.D.
|
Chief Medical Officer | -- | -- | 1970 |
|
Mr. Arjun Prasad M.B.A., M.P.H.
|
Chief Commercial Officer | -- | -- | 1978 |
Compass Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 39
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
November 5, 2026 at 12:30 PM UTC
Compass Therapeutics, Inc. Earnings Date
